References
1.(WHO) WHO. Weekly epidemiological update on
COVID-19, May 2022.
2.Götzinger F, Santiago-García B, Noguera-Julián A,
Lanaspa M, Lancella L, Calò Carducci FI, et al. COVID-19 in children and
adolescents in Europe: a multinational, multicentre cohort study. The
Lancet Child & Adolescent Health. 2020 2020/09/01/;4(9):653-61.
3.Woodruff RC, Campbell AP, Taylor CA, Chai SJ,
Kawasaki B, Meek J, et al. Risk factors for severe COVID-19 in children.
Pediatrics. 2022;149(1).
4.Williams P, Koirala A, Saravanos G, Lopez L, Glover
C, Sharma K, et al. COVID-19 in children in NSW, Australia, during the
2021 Delta outbreak: Severity and Disease spectrum. medRxiv. 2021.
5.Delahoy MJ, Ujamaa D, Whitaker M, O’Halloran A,
Anglin O, Burns E, et al. Hospitalizations associated with COVID-19
among children and adolescents—COVID-NET, 14 states, March 1,
2020–August 14, 2021. Morbidity and Mortality Weekly Report.
2021;70(36):1255.
6.Ward JL, Harwood R, Smith C, Kenny S, Clark M, Davis
PJ, et al. Risk factors for PICU admission and death among children and
young people hospitalized with COVID-19 and PIMS-TS in England during
the first pandemic year. Nature medicine. 2021:1-8.
7.Shi Q, Wang Z, Liu J, Wang X, Zhou Q, Li Q, et al.
Risk factors for poor prognosis in children and adolescents with
COVID-19: A systematic review and meta-analysis. EClinicalMedicine.
2021;41:101155.
8.Lee SW, Ha EK, Yeniova AÖ, Moon SY, Kim SY, Koh HY,
et al. Severe clinical outcomes of COVID-19 associated with proton pump
inhibitors: a nationwide cohort study with propensity score matching.
Gut. 2021;70(1):76-84.
9.Mukkada S, Bhakta N, Chantada GL, Chen Y, Vedaraju
Y, Faughnan L, et al. Global characteristics and outcomes of SARS-CoV-2
infection in children and adolescents with cancer (GRCCC): a cohort
study. The Lancet Oncology. 2021;22(10):1416-26.
10.Marlais M, Wlodkowski T, Vivarelli M, Pape L,
Tönshoff B, Schaefer F, et al. The severity of COVID-19 in children on
immunosuppressive medication. The Lancet Child & Adolescent Health.
2020;4(7):e17-e8.
11.Pedersen RN, Calzolari E, Husby S, Garne E.
Oesophageal atresia: prevalence, prenatal diagnosis and associated
anomalies in 23 European regions. Arch Dis Child. 2012 Mar;97(3):227-32.
12.Cassina M, Ruol M, Pertile R, Midrio P, Piffer S,
Vicenzi V, et al. Prevalence, characteristics, and survival of children
with esophageal atresia: A 32-year population-based study including
1,417,724 consecutive newborns. Birth Defects Res A Clin Mol Teratol.
2016 Jul;106(7):542-8.
13.Sulkowski JP, Cooper JN, Lopez JJ, Jadcherla Y,
Cuenot A, Mattei P, et al. Morbidity and mortality in patients with
esophageal atresia. Surgery. 2014;156(2):483-91.
14.Koumbourlis AC, Belessis Y, Cataletto M, Cutrera R,
DeBoer E, Kazachkov M, et al. Care recommendations for the respiratory
complications of esophageal atresia‐tracheoesophageal fistula. Pediatric
Pulmonology. 2020;55(10):2713-29.
15.Yang C-F, Soong W-J, Jeng M-J, Chen S-J, Lee Y-S,
Tsao P-C, et al. Esophageal atresia with tracheoesophageal fistula: ten
years of experience in an institute. Journal of the Chinese Medical
Association. 2006;69(7):317-21.
16.Shah R, Varjavandi V, Krishnan U. Predictive
factors for complications in children with esophageal atresia and
tracheoesophageal fistula. Diseases of the Esophagus. 2015;28(3):216-23.
17.van Lennep M, Singendonk MM, Dall’Oglio L, Gottrand
F, Krishnan U, Terheggen-Lagro SW, et al. Oesophageal atresia. Nature
Reviews disease primers. 2019;5(1):1-21.
18.Cartabuke RH, Lopez R, Thota PN. Long-term
esophageal and respiratory outcomes in children with esophageal atresia
and tracheoesophageal fistula. Gastroenterology report. 2016;4(4):310-4.
19.Somppi E, Tammela O, Ruuska T, Rahnasto J, Laitinen
J, Turjanmaa V, et al. Outcome of patients operated on for esophageal
atresia: 30 years’ experience. Journal of pediatric surgery.
1998;33(9):1341-6.
20.Porcaro F, Valfré L, Aufiero LR, Dall’Oglio L, De
Angelis P, Villani A, et al. Respiratory problems in children with
esophageal atresia and tracheoesophageal fistula. Italian Journal of
Pediatrics. 2017;43(1):1-9.
21.Mousa H, Krishnan U, Hassan M, Dall’Oglio L, Rosen
R, Gottrand F, et al. How to care for patients with EA-TEF: the known
and the unknown. Current gastroenterology reports. 2017;19(12):1-15.
22.Flatrès C, Aumar M, Ley D, Sfeir R, Nicolas A,
Bonnevalle M, et al. Prevalence of acid gastroesophageal reflux disease
in infants with esophageal atresia/tracheoesophageal fistula. Pediatric
Research. 2022;91(4):977-83.
23.Vergouwe FW, van Wijk MP, Spaander MC, Bruno MJ,
Wijnen RM, Schnater JM, et al. Evaluation of gastroesophageal reflux in
children born with esophageal atresia using pH and impedance monitoring.
Journal of pediatric gastroenterology and nutrition. 2019;69(5):515.
24.Catalano P, Di Pace MR, Caruso AM, Casuccio A, De
Grazia E. Gastroesophageal reflux in young children treated for
esophageal atresia: evaluation with pH-multichannel intraluminal
impedance. Journal of pediatric gastroenterology and nutrition.
2011;52(6):686-90.
25.Esposito S, Caramelli F, Principi N. What are the
risk factors for admission to the pediatric intensive unit among
pediatric patients with COVID-19? Italian Journal of Pediatrics.
2021;47(1):1-4.
26.Farrar DS, Drouin O, Hepburn CM, Baerg K, Chan K,
Cyr C, et al. Risk factors for severe COVID-19 in hospitalized children
in Canada: A national prospective study from March 2020—May 2021.
medRxiv. 2022.
27.Pranata R, Huang I, Lawrensia S, Henrina J, Lim MA,
Lukito AA, et al. Proton pump inhibitor on susceptibility to COVID-19
and its severity: a systematic review and meta-analysis. Pharmacological
Reports. 2021;73(6):1642-9.